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Abstract
Introduction Previously, an app has been developed for
healthcare professionals (HCPs) and patients to report
adverse drug reactions (ADRs) to national medicines
agencies and to receive drug safety information.
Objective This study aimed to assess (1) European HCPs’ and
patients’ interest in an app for this two-way risk communica-
tion; (2) their preferences and perceptions towards specific app
characteristics; and (3) which HCPs and patients are particu-
larly interested in the app. In addition, these aspects were
studied specifically for the countries where such an app was
already available, i.e. Croatia, The Netherlands, and The UK.
Methods European HCPs and patients were asked to
complete a web-based survey developed in the context of
the Web-Recognizing Adverse Drug Reactions (Web-
RADR) project. Data on app interest and preferences and
perceptions towards app characteristics were analysed
descriptively. Logistic regression analyses were conducted
to assess the association of HCP characteristics and patient
characteristics on the level of interest in the app (i.e. very
interested vs. not/somewhat interested).
Results In total, 399 HCPs and 656 patients completed the
survey. About half of the patients (48%; ranging from 38%
from The Netherlands to 54% from The UK), and 61% of the
HCPs (ranging from 42% from The Netherlands to 54% from
The UK) were very interested in the app. A faster means of
reporting ADRs and easier access to the reporting form were
the main perceived benefits. HCPs and patients who already
use a health app were particularly interested in the app
(HCPs: odds ratio [OR] 3.52; 95% confidence interval [CI]
1.96–6.30, patients: OR 1.64; 95% CI 1.19–2.27).
Conclusions An app is positively perceived by HCPs and
patients for reporting ADRs quickly and for receiving drug
safety information from national medicines agencies. In
particular, HCPs and patients who already use other health
apps were interested in the app.
Key Points
Interest in an app for two-way risk communication
(i.e. to report adverse drug reactions [ADRs] to
national medicines agencies and to receive drug
safety information) is high among healthcare
professionals (HCPs) and patients.
The app should be a faster way to report ADRs than
conventional reporting options and should preferably
offer additional information about drug–drug
interactions and previously reported ADRs.
Strategies to disseminate an app on two-way risk
communication could focus on targeting HCPs and
patients who already use a health app since these
persons were particularly interested in the app.
The members of IMI Web-RADR Work Package 3b Consortium are
listed in acknowledgements.
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1 Introduction
Healthcare professionals (HCPs) and patients have access
to a plethora of health-related mobile apps but not every
person is equally interested in such apps. Recently, a health
app developed in the context of the Web-Recognizing
Adverse Drug Reactions (Web-RADR) project (https://
web-radr.eu/) was added to the available health-related
apps. The goal of this app is to provide two-way risk
communication, defined as the possibility to report adverse
drug reactions (ADRs) to national medicines agencies/
pharmacovigilance centres, and to receive drug safety
information from these agencies [1]. Previously, in a
qualitative study, we identified various factors that may
influence the use of this app and showed that HCPs and
patients were generally positive about its development [2].
However, these aspects should be validated in a larger
population.
Considering the plethora of new technologies, including
apps, theoretical models have been developed attempting
to identify factors that influence the uptake of the new
technology. An example is the Unified Theory of Accep-
tance and Use of Technology, which states that user
characteristics play a moderating role in the acceptance of
technology [3]. This indicates that not every HCP or
patient will be interested in the app. Several studies have
investigated whether interest in health apps is influenced by
characteristics such as age, ethnicity/race, gender, current
use of a health app, inability to work, income, educational
degree, clinical characteristics or having a family member
with a specific disease [4–8]. Although the studies con-
sistently show that older people are generally less inter-
ested in health apps than younger people [4–8], the
literature is inconclusive about other user characteristics.
For instance, Latinos/Hispanics were less interested in one
study [6] but more interested in another study [8] than
Caucasians/white people. Likewise, one study showed that
males were slightly less interested than females [7],
whereas another study showed no gender differences [8].
The previous studies conducted in the USA [5–8] or
Asia (i.e. Singapore) [4] focused on patients or the general
population, and assessed a person’s interest in a health app
in general [6–8] or in apps to support adherence or self-
management [4, 5]. A recent study about the VigiBIP app,
developed by the Toulouse University Pharmacovigilance
Center for two-way risk communication, suggests that
patients are interested in the app and that different ADRs
may by reported via the app compared with conventional
methods [9]. However, more studies on characteristics of
HCPs and patients on their interest in apps for communi-
cating health-related issues with national medicines agen-
cies are needed.
The aim of the current study was to assess (1) European
HCPs’ and patients’ interest in an app for two-way risk
communication; (2) their preferences and perceptions
towards specific characteristics of the app; and (3) which
HCPs and patients are particularly interested in such an
app. In addition, these aspects were specifically studied for
the countries where such an app was already available, i.e.
Croatia, The Netherlands and The UK. This knowledge can
be used by national medicines agencies in the development
or improvement of an app for two-way risk communication
and in the development of strategies to inform potential
users about the existence of the app.
2 Methods
2.1 Study Design and Survey Development
In this cross-sectional study, data were collected between
July and October 2016 using web-based surveys. Two
surveys (i.e. one for HCPs and one for patients) were
developed in English by members of the Web-RADR
project (see Electronic Supplementary Material 1 and 2 for
the HCP and patient survey, respectively). The English-
language surveys were translated by an official translation
agency into Croatian, Dutch, French, German, Portuguese
and Spanish. Web-RADR members checked whether the
translations had the same meaning as the English version.
The web-based format of the surveys was created using
Unipark software (http://unipark.com/en/). A separate link
was available for the HCP and patient survey in each of the
languages.
The content of the surveys was based on the results of a
qualitative study [2], input from members of other work
packages of the Web-RADR project, and various HCP and
patient organisations. The patient survey contained ques-
tions about ADR reporting in general; their opinion of an
app to report ADRs, an app to receive safety information,
and an app for two-way risk communication; reporting
ADRs through an app of the national medicines agency;
safety information and receiving such information through
an app; and, finally, some general questions such as age,
gender and the country in which they lived at the time of
survey completion.
In some questions, the name of the national medicines
agency/pharmacovigilance centre was mentioned. The
Agenciju za lijekove i medicinske proizvode (HALMED),
Nederlands Bijwerkingencentrum (Lareb), Medicines and
Health Regulatory Agency (MHRA), l’Agence nationale
de se´curite´ du me´dicament et des produits de sante´
(ANSM), Bundesinstitutes fu¨r Arzneimittel und Medizin-
produkte, Autoridade Nacional do Medicamento e Produ-
tos de Sau´de (INFARMED) and la Agencia Espan˜ola del
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Medicamento y Productos Sanitarios (AEMPS) were
mentioned in the Croatian, Dutch, English, French, Ger-
man, Portuguese and Spanish versions of the survey,
respectively.
Participants gave their implied consent to participate in
the study by voluntarily completing the survey.
2.2 Participants and Data Collection
Any HCP or patient in Europe familiar with mobile apps
was eligible to participate in this study. All HCPs were
considered to be familiar with apps. Patients were informed
that they should only complete the survey if they were
familiar with apps. Various channels were used to reach
HCPs and patients. For instance, European and national
HCP and patient organisations distributed the survey
among members via direct e-mail or advertisements on
their websites and/or in their newsletters. The survey was
also announced on Facebook and Twitter accounts, for
instance on the account of the Web-RADR project.
Recruitment strategies focused particularly on reaching
HCPs and patients in Croatia, The Netherlands and The UK
since the Web-RADR app on two-way risk communication
was available in these countries at the time of this study.
The pharmacovigilance centres in Croatia, The Netherlands
and The UK also distributed the survey, for instance by
posting a message on their respective websites. To
encourage response rates, survey completers had the option
to participate in a prize draw to win a €50 coupon.
2.3 Outcome Measure: Interest in the App
The outcome measure of this study was responders’ interest
in an app for two-way risk communication. Responders
were asked to rate on a 4-point Likert scale to what extent
they were interested in such an app (Table 1). Responders
could also indicate that they did not know whether they had
interest in the app.
2.4 Determinants: App Characteristics
Expectations and actual characteristics of an app may
influence someone’s intention to download and use an app
[3]. Therefore, responders were asked about their prefer-
ences and perceptions regarding an app for two-way risk
communication. For this, questions were asked about per-
ceived benefits in using the app, the type of news of
interest, interest in other functions in the app and the
protection of the app. In addition, responders were asked
about their intention to download an app for two-way risk
communication.
2.5 Determinants: Healthcare Professional (HCP)/
Patient Characteristics
The following HCP characteristics were assessed as
determinants for HCPs’ interest in an app for two-way risk
communication: age, gender, how often they already used
health apps and whether they had ever reported an ADR to
the national medicines agency. For patients, the following
characteristics were assessed: age, gender, educational
level, number of medicines, how often they already used
health apps, whether they had ever experienced an ADR
and whether they were aware they could report ADRs to
the national medicines agency (Table 1).
2.6 Analyses
Descriptive statistics are presented for HCPs and patients
separately. In addition, this is presented for countries in
which the app was already available. Completers of the
Croatian, Dutch or English version of the survey who
indicated they were living in these countries at the time of
the survey were included in these country-specific analy-
ses. Differences across these countries were tested using
Chi-squared (v2) tests. Three post hoc v2-tests were con-
ducted in the case of P\0.05 to test which countries dif-
fered from each other. The Bonferroni correction was
applied for these post hoc analyses to correct for multiple
testing. This implies that P values\0.016 were considered
statistically significant.
Logistic regression analyses were conducted to assess
associations between responder characteristics and the
dichotomised outcome measure, expressing a high interest
in the app. For this, being very interested was contrasted
with being somewhat or not interested (Table 1). In sen-
sitivity analyses using generalised ordered logit models
[10, 11], we assessed whether this dichotomisation resulted
in a loss of information. Responders were excluded from
the logistic regression analyses and generalised ordered
logit models when they (1) selected another answer option
than male/female on the question about their gender; (2)
did not answer or answered ‘don’t know’ on the question
about the app interest (outcome variable); or (3) did not
answer a question that was used as a determinant in these
analyses.
All analyses were conducted using Stata version 13
(Stata Corp., College Station, TX, USA). Microsoft Excel
2010 (Microsoft Corp., Redmond, WA, USA) was used for
the graphical presentation of the results.
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Table 1 Questions and answer options used as outcome variable and determinants
Variable Question Answer options Type of variable in analyses Analyses of
HCPs/patients
Outcome variable
App interest In general, how interested would you be in an app of
the\national medicines agency[ that you can use
for both, reporting side effects/adverse drug
reactions and receiving safety information?
Not interested at all
Somewhat
interested
Interested
Very interested
Don’t know
Dichotomous: not/(somewhat)
interested vs. very interested
Don’t know ? excluded
HCPs and
patients
Determinants
Age What is your age? Continuous Continuous HCPs and
patients
Gender What is your gender? Male
Female
Other/prefer not to
say
Dichotomous: male vs. female
Other/prefer not to
say ? excluded
HCPs and
patients
Educational
level
What is your highest level of education completed? No formal education
or below
Primary education
Lower secondary
education
Upper secondary
education
Post-secondary but
non-tertiary
education
First stage of
tertiary education
Second stage of
tertiary education
Dichotomous: low/secondary
education vs. tertiary
education (first and second
stage)
Patients
Number of
medicines
How many different medicines are prescribed to you
at the moment?
0
1
2
3
4
5 or more
Categorical: 0 medicines; 1–4
medicines (reference
category);C 5 medicines
Patients
Use health
apps
How often do you use a health app? Daily
Weekly
Monthly or less
often
Never
Dichotomous: never vs. other
answer options
HCPs and
patients
Experience of
ADRs
Have you ever experienced a side effect of a
medicine that you take or have taken in the past?
Yes
No
Don’t know/don’t
remember
Dichotomous: no/don’t know
vs. yes
Patients
Awareness of
reporting
ADRs
Are you aware that you can report experienced side
effects to the\national medicines agency[?
Yes
No
I have never heard
of the\national
medicines
agency[
Dichotomous: no/I have never
heard of the\national
medicines agency[ vs. yes
Patients
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3 Results
3.1 Characteristics of the Responders
3.1.1 HCPs
In total, 399 HCPs completed the survey: 192 were from
Croatia, 62 were from The Netherlands, 83 were from The
UK and 62 (16%) were from other European countries (i.e.
countries where the app was not rolled out) (see Electronic
Supplementary Material 3). The age of the responders
ranged from 20 to 71 years and most of the responders
were women (68%). Sixteen percent of the 399 HCPs
indicated they had never used a health app. More than half
of the HCPs had at least heard about the Web-RADR app.
3.1.2 Patients
There were 656 patients who completed the survey, of
whom 136 were from Croatia, 187 were from The
Netherlands, and 100 were from The UK. The remaining
233 (36%) patients were from other European countries
(i.e. countries where the app was not rolled out) (Electronic
Supplementary Material 3). The age of the participants
ranged from 12 to 89 years and most of the responders
were women (65%). Nineteen percent of the 656 patients
were not prescribed any medicines. Half of the patients
indicated they had never used a health app even though
they had to be familiar with apps in general to complete the
survey, and most were not aware of the Web-RADR app
(77%).
3.2 Outcome Measure: Interest in the App
Responders were generally interested in the app for two-
way risk communication (Fig. 1). In total, 61% of the
HCPs were very interested in such an app, which ranged
from 42% in The Netherlands to 66% in Croatia (Fig. 1a).
HCPs were somewhat more interested in the app than
patients. About half of the patients (48%) were very
interested in the app, which ranged from 38% in The
Netherlands to 54% in The UK (Fig. 1b). Interest in an app
for two-way risk communication was somewhat higher
than interest in an app with single functionality (i.e.
reporting of ADRs or receiving safety information).
3.3 Determinants: App Characteristics
3.3.1 Perceived Benefits in Using the App
With respect to the reporting functionality of the app, most
of the HCPs and patients indicated that a faster way to
report ADRs and easier access to the ADR reporting form
were potential benefits of using the app. These answer
options were selected by 83 and 73% of the HCPs,
respectively (Table 2) and by 85 and 72% of patients,
respectively (Table 3).
Keeping up-to-date with the latest drug safety news
(84%) and increasing their drug safety knowledge (76%)
were important benefits perceived by HCPs on using an
app. The possibility to select medicines of interest was seen
as the least beneficial option for HCPs (47%) (Table 2).
Most of the patients saw it as a benefit that the app would
allow them to check whether a symptom has previously
been reported as an ADR (72%) (Table 3).
3.3.2 Type of News of Interest
HCPs liked an option to receive news about newly iden-
tified drug–drug interactions most (82%), followed by
information about new indications of a drug (75%)
(Table 2). They also liked the option to receive news for all
approved marketed drugs (37%). However, the ‘work-/
preference-specific’ answer options (i.e. drugs that they
prescribe, drugs related to their work and all drugs they are
interested in) were together selected by about 60% of the
HCPs (Table 2).
Table 1 continued
Variable Question Answer options Type of variable in analyses Analyses of
HCPs/patients
Report ADR
to national
medicines
agency
Have you ever reported an adverse drug reaction
experienced by your patients to the\national
medicines agency[?
Yes
No
Don’t know/don’t
remember
Dichotomous: no/don’t know
vs. yes
HCPs
ADR adverse drug reaction, HCPs healthcare professionals
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Patients liked an option to receive drug safety updates
(i.e. each newly identified severe ADR of a drug) most
(84%), followed by newly identified interactions between
drugs (71%) (Table 3). Only 6% of the patients liked an
option to receive news about all marketed drugs.
3.3.3 Interest in Other Functions in the App
Many HCPs and patients selected additional functions that
they would like in an app for two-way risk communication.
Additional information functions were more often selected
than additional reporting functions (Tables 2, 3). For HCPs
this included information about known interactions
between drugs (76%), followed by information about how
to resolve an ADR (75%) and an overview of alternative
drugs to the one for which an ADR is experienced (71%).
Most patients liked an overview of ADRs previously
reported by others (73%) and patient information leaflets
(72%).
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100%
Not interested at all Somewhat interested Interested
Very interested Mean (on a scale from not interested at all to very interested) 
0%
20%
40%
60%
80%
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* Total a Netherlands UK
Total a Netherlands UK* 
Fig. 1 a Healthcare
professionals’ interest in an app
to report adverse drug reactions
(8 responders were excluded; 4
did not complete this question
and 4 answered ‘I don’t know’),
to receive safety information (5
responders were excluded; 4 did
not complete this questions and
1 answered ‘I don’t know’), and
for both (i.e. two-way risk
communication) (1 responder
did not complete this question
and was excluded). b Patients’
interest in an app to report
adverse drug reactions (15
responders were excluded; 2 did
not complete this question and
13 answered ‘I don’t know’), to
receive safety information (14
responders were excluded; 1 did
not complete this question and
13 answered ‘I don’t know’),
and for both (15 responders
were excluded; 3 did not
complete this question and 12
answered ‘I don’t know’). *All
European responders. ADRs
adverse drug reactions
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Table 2 Healthcare professionals’ preferences and perceptions towards various characteristics of the app
Totala Croatia The Netherlands UK P-value
Perceived benefits in using the app
What benefits are there for you in using this app?b,c
Faster way to report 317 (83) 152 (80) 51 (86) 62 (84) 0.532
Easier access to ADR report form 276 (73) 131 (69) 39 (66) 61 (82) 0.059
Continue report at a later stage 232 (61) 124 (66) 29 (49) 49 (66) 0.058
Upload a photo 203 (53) 91 (48) 34 (58) 40 (54) 0.383
Store previously reported ADRs 200 (53) 115 (61) 15 (25) 37 (50) \0.001
HR–NL:\ 0.001
NL–UK: 0.004
HR–UK: 0.109
Complete report offline and send it later 179 (47) 90 (48) 19 (32) 39 (53) 0.048
HR–NL: 0.037
NL–UK: 0.018
HR–UK: 0.458
What are the likely benefits in using an app of the\national medicines agency[ to receive safety information?c,d
It will keep me up-to-date 318 (84) 159 (83) 45 (80) 68 (88) 0.429
Increased knowledge 290 (76) 155 (81) 35 (63) 58 (75) 0.014
HR–NL: 0.004
NL–UK: 0.111
HR–UK: 0.285
Check whether symptom has been reported as ADR 248 (65) 125 (65) 33 (59) 55 (71) 0.322
Possibility to receive notifications 242 (64) 112 (59) 32 (57) 58 (75) 0.026
HR–NL: 0.842
NL–UK: 0.027
HR–UK: 0.010
Select medicine of interest 180 (47) 84 (44) 19 (34) 42 (55) 0.058
Type of news of interest
What type of news about medicines would be useful to you in an app?e,f
Newly identified drug–drug interactions 314 (82) 166 (87) 40 (68) 62 (79) 0.003
HR–NL: 0.001
NL–UK: 0.120
HR–UK: 0.124
New indications of a drug 286 (75) 165 (86) 28 (47) 51 (65) \ 0.001
HR–NL:\ 0.001
NL–UK: 0.035
HR–UK:\ 0.001
NCA communications 273 (71) 139 (73) 32 (54) 60 (77) 0.009
HR–NL: 0.007
NL–UK: 0.005
HR–UK: 0.482
Drugs that are taken off the market 262 (68) 126 (66) 37 (63) 58 (74) 0.288
Changes in the PIL 247 (64) 130 (68) 27 (46) 54 (69) 0.004
HR–NL: 0.002
NL–UK: 0.006
HR–UK: 0.852
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Table 2 continued
Totala Croatia The Netherlands UK P-value
DHPCs 245 (64) 135 (71) 34 (58) 42 (54) 0.016
HR–NL: 0.061
NL–UK: 0.659
HR–UK: 0.008
Educational materials 186 (49) 106 (56) 17 (29) 32 (41) 0.001
HR–NL:\ 0.001
NL–UK: 0.140
HR–UK: 0.031
Whether re-assessment is ongoing 162 (42) 74 (39) 16 (27) 41 (53) 0.009
HR–NL: 0.104
NL–UK: 0.003
HR–UK: 0.038
Discontinuation of black triangle 149 (39) 77 (40) 9 (15) 46 (59) \ 0.001
HR–NL:\ 0.001
NL–UK:\ 0.001
HR–UK: 0.005
For which medicines would you like to receive news?g,h
All approved marketed drugs 137 (37) 61 (32) 20 (35) 33 (45) 0.001
HR–NL: 0.001
NL–UK: 0.534
HR–UK: 0.007
All drugs I am interested in 72 (19) 44 (23) 8 (14) 9 (12)
Drugs related to my work 98 (26) 60 (32) 10 (18) 15 (20)
Drugs that I prescribe 66 (18) 23 (12) 19 (33) 17 (23)
Interest in other functions in the app
Please think about an app that you can use for both reporting ADRs and receiving safety information. Which other information functions would
you like in such an app?f,i
Interactions between drugs 303 (76) 176 (92) 34 (56) 50 (61) \ 0.001
HR–NL:\ 0.001
NL–UK: 0.529
HR–UK:\ 0.001
How to resolve an ADR 296 (75) 148 (77) 42 (69) 57 (70) 0.270
Alternative drugs to the one causing the ADR 282 (71) 139 (72) 43 (70) 54 (66) 0.554
Drug product information 269 (68) 144 (75) 30 (49) 53 (65) 0.001
HR–NL:\ 0.001
NL–UK: 0.064
HR–UK: 0.080
Overview of previously reported ADRs 251 (63) 110 (57) 43 (70) 52 (63) 0.163
Prediction model 218 (55) 99 (52) 30 (49) 49 (60) 0.365
Quality alerts 154 (39) 72 (38) 15 (25) 41 (50) 0.008
HR–NL: 0.064
NL–UK: 0.002
HR–UK: 0.054
Which other reporting functions would you like in such an app?f,j
When the medicine cannot be dispensed 231 (68) 124 (72) 29 (64) 46 (66) 0.460
Medicine defects 216 (64) 105 (61) 23 (51) 50 (71) 0.083
Medication errors 205 (60) 106 (62) 18 (40) 44 (63) 0.023
HR–NL: 0.009
NL–UK: 0.016
HR–UK: 0.858
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3.3.4 Protection of the App
Most of the HCPs preferred to use an app for two-way risk
communication via an automatic login after entering their
e-mail address and password once (70%) (Table 2).
Although most patients also prefer an automatic login, this
preference was less pronounced (57%) (Table 3).
3.3.5 Intention to Download the App
In total, 69% of the HCPs and 52% of the patients indicated
that it is very likely that they will download the app. Only
2% of the HCPs (Table 2) and 6% of the patients (Table 3)
indicated that this is not likely at all.
3.3.6 Countries in Which the App was Already Available
HCPs from Croatia appeared to have more positive views
on potential benefits of the app, the addition of other
functionalities and the intention to download the app than
HCPs from The Netherlands and The UK (Table 2). HCPs
from The Netherlands generally had a more negative view.
HCPs from The UK were more positive to receive news in
the app about discontinuation of a black triangle for a drug
(59 vs. 40% in Croatia and 15% in The Netherlands;
overall P\0.001) and to receive quality alerts (50 vs. 38%
in Croatia and 25% in The Netherlands; overall
P = 0.008).
Patients from The UK had more positive views on
various benefits of using the app than patients from Croatia
and The Netherlands (Table 3). Patients from The
Netherlands were more negative, particularly regarding
potential benefits of continuing an unfinished report at a
later moment (33 vs. 48% in Croatia and 56% in The UK;
overall P = 0.001) and of not having to contact a HCP for
every symptom they experience (24 vs. 50% in Croatia and
53% in The UK; overall P\0.001). In addition, they were
less positive about patient information leaflets (61 vs. 76%
in both Croatia and The UK; overall P = 0.004), infor-
mation on where to get help (36 vs. 63% in Croatia and
Table 2 continued
Totala Croatia The Netherlands UK P-value
Protection of the app
How should an app for you to report ADRs and receive safety information of medicines be protected?k,l
Entering an email address and password 109 (30) 63 (34) 11 (20) 21 (29) 0.152
Automatic login 257 (70) 122 (66) 43 (80) 51 (71)
Intention to download the app
How likely are you to download a free, limited space-taking app to report ADRs and receive safety information of medicines on your device?
Not at all likely 9 (2) 1 (1) 1 (2) 6 (7) \ 0.001
HR–NL:\ 0.001
NL–UK: 0.122
HR–UK:\ 0.001
Slightly likely 32 (8) 6 (3) 13 (21) 8 (10)
Moderately likely 82 (21) 35 (18) 15 (24) 19 (23)
Very likely 276 (69) 150 (78) 33 (53) 50 (60)
Data are given as n (%)
ADRs adverse drug reactions, DHPCs direct healthcare professional communications, HR Croatia, NCA national competent authority, NL
Netherlands, PIL patient information leaflet
aAll European responders
bThe number of responders that do not want to use an app to report ADRs was 12 and the number of responders that selected ‘none’ was 7. 19
responders selected ‘Other’
cPercentages are calculated excluding the responders who selected ‘None’ and those who selected ‘I do not want to use an app to report ADRs/
receive safety information’
d6 responders selected ‘None’, 13 responders selected ‘I do not want to use an app to receive safety information’ and 6 selected ‘Other’
e16 responders indicated that they did not want to receive safety information through an app and 10 selected ‘Other’
fPercentages are calculated excluding those who selected ‘No other information/reporting functions’ or ‘I do not want to receive safety
information through an app’
g15 responders indicated ‘None’ and 11 responders selected ‘Other’
hPercentages are calculated excluding those who selected ‘None’ and ‘Other’
i2 responders were not interested in any other type of information function and 37 selected ‘Other’
jThe number of responders not interested in any other type of reporting function was 59 and 20 selected ‘Other’
kOne responder did not answer this question and 32 responders selected ‘Other’
lPercentages are calculated excluding the responders who selected ‘Other’
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Table 3 Patients’ preferences and perceptions towards various characteristics of the app
Totala Croatia The Netherlands UK P-value
Perceived benefits in using the app
What are the likely benefits for you in using this app?b,c
Faster way to report 513 (85) 111 (85) 138 (85) 76 (81) 0.592
Easier access to report form 434 (72) 94 (72) 103 (64) 75 (80) 0.020
HR–NL: 0.114
NL–UK: 0.007
HR–UK: 0.199
Store previous reports 290 (48) 63 (48) 70 (43) 46 (49) 0.569
Upload a photo 288 (47) 66 (51) 63 (39) 51 (54) 0.030
HR–NL: 0.042
NL–UK: 0.017
HR–UK: 0.606
Continue a report at a later moment 264 (43) 62 (48) 53 (33) 53 (56) 0.001
HR–NL: 0.009
NL–UK:\ 0.001
HR–UK: 0.199
Complete report offline and send it later 262 (43) 53 (41) 54 (33) 50 (53) 0.008
HR–NL: 0.190
NL–UK: 0.002
HR–UK: 0.066
What are the likely benefits for you in using an app of the\national medicines agency[to receive safety information?c,d
Check whether symptom has been reported as ADR 441 (72) 89 (69) 106 (65) 73 (79) 0.048
HR–NL: 0.433
NL–UK: 0.014
HR–UK: 0.086
Increased knowledge 388 (63) 84 (65) 90 (55) 62 (67) 0.079
It will keep me up-to-date 378 (62) 60 (47) 112 (68) 66 (72) \ 0.001
HR–NL:\ 0.001
NL–UK: 0.565
HR–UK:\ 0.001
Possibility to receive notifications 341 (56) 42 (33) 84 (51) 62 (67) \ 0.001
HR–NL: 0.001
NL–UK: 0.012
HR–UK:\ 0.001
Select medicines of interest 311 (51) 51 (40) 70 (43) 52 (57) 0.033
HR–NL: 0.587
NL–UK: 0.033
HR–UK: 0.013
Increased confidence when talking to my HCP 283 (46) 50 (39) 75 (46) 53 (58) 0.021
HR–NL: 0.231
NL–UK: 0.068
HR–UK: 0.006
No need to contact HCP for every symptom 247 (40) 65 (50) 40 (24) 49 (53) \ 0.001
HR–NL:\ 0.001
NL–UK:\ 0.001
HR–UK: 0.674
Type of news of interest
What type of news about medicines would be useful to you in an app?e,j
S. T. Vries et al.
Table 3 continued
Totala Croatia The Netherlands UK P-value
Safety updates 520 (84) 104 (78) 139 (84) 77 (85) 0.317
Newly identified drug interactions 439 (71) 85 (64) 105 (64) 79 (87) \0.001
HR–NL: 0.961
NL–UK:\ 0.001
HR–UK: 2009\ 0.001
Changes in the PIL 421 (68) 84 (63) 100 (61) 71 (78) 0.015
HR–NL: 0.652
NL–UK: 0.005
HR–UK: 0.018
New approved used of a drug 324 (53) 69 (52) 69 (42) 43 (47) 0.221
Whether drug review is ongoing 310 (50) 57 (43) 64 (39) 55 (60) 0.003
HR–NL: 0.477
NL–UK: 0.001
HR–UK: 0.010
News on how to take/store the drug 305 (49) 72 (54) 81 (49) 33 (36) 0.029
HR–NL: 0.386
NL–UK: 0.048
HR–UK: 0.008
Experiences of other users of the drug 292 (47) 75 (56) 79 (48) 33 (36) 0.012
HR–NL: 0.144
NL–UK: 0.073
HR–UK: 0.003
Drugs that are temporarily out of stock 243 (39) 45 (34) 65 (39) 28 (31) 0.342
For which medicines would you like to receive news?g,h
All approved marketed drugs 36 (6) 10 (8) 8 (5) 7 (8) \0.001
HR–NL:\ 0.001
NL–UK: 0.112
HR–UK: 0.001
All drugs I am interested in 161 (27) 52 (40) 20 (12) 20 (22)
All drugs to treat my disease 167 (28) 35 (27) 42 (26) 17 (19)
Drugs prescribed to me 241 (40) 33 (25) 93 (57) 46 (51)
Interest in other functions in the app
Please think about an app that you can use for both reporting side effects and receiving safety information. Which other functions would you
like in such an app?i,j
Overview of ADRs previously reported 458 (73) 94 (70) 116 (67) 65 (68) 0.846
PIL 450 (72) 102 (76) 105 (61) 72 (76) 0.004
HR–NL: 0.004
NL–UK: 0.013
HR–UK: 0.954
Store list of medicines 405 (64) 71 (53) 102 (59) 71 (75) 0.003
HR–NL: 0.295
NL–UK: 0.010
HR–UK: 0.001
Information on where to get help 368 (59) 84 (63) 63 (36) 56 (59) \0.001
HR–NL:\ 0.001
NL–UK:\ 0.001
HR–UK: 0.567
Reminder to take medicines 321 (51) 79 (59) 54 (31) 54 (57) \0.001
HR–NL:\ 0.001
NL–UK:\ 0.001
HR–UK: 0.750
Option to report medicine defects 321 (51) 69 (51) 83 (48) 53 (56) 0.468
Interest in an App for Two-Way Risk Communication
59% in The UK; overall P\0.001), a reminder to take
medicines (31 vs. 59% in Croatia and 57% in The UK;
overall P\0.001), and a functionality to chat with others
about their own experiences (14 vs. 31% in Croatia and
27% in The UK; overall P = 0.001).
3.4 Determinants: HCP/Patient Characteristics
Of the 399 HCPs and 656 patients who completed the
survey, 390 and 636, respectively, were included in the
analyses to assess the association between HCP/patient
characteristics and being interested in the app (Electronic
Supplementary Material 4).
3.4.1 HCP Characteristics
Of the four determinants included in the analyses of the
HCPs, only the use of a health app was significantly
associated with interest in the app. HCPs who at least
sometimes use a health app were more often very interested
than those who never use such an app (odds ratio [OR]
3.52; 95% confidence interval [CI] 1.96–6.30) (Fig. 2a).
The sensitivity analyses per country of interest showed that
Table 3 continued
Totala Croatia The Netherlands UK P-value
Learn from other patient experiences 299 (48) 77 (57) 73 (42) 50 (53) 0.024
HR–NL: 0.008
NL–UK: 0.101
HR–UK: 0.469
Chat with others about own experiences 140 (22) 41 (31) 24 (14) 26 (27) 0.001
HR–NL:\ 0.001
NL–UK: 0.007
HR–UK: 0.597
Protection of the app
How should an app for you to report side effects and receive safety information of medicines be protected?f,k
Entering an email address and password 255 (43) 50 (39) 58 (38) 40 (44) 0.606
Automatic login 332 (57) 79 (61) 96 (62) 51 (56)
Intention to download the app
How likely are you to download a free, limited space taking app to report side-effects and receive safety information of medicines on your
device?l
Not at all likely 37 (6) 4 (3) 19 (10) 7 (7) 0.001
HR–NL:\ 0.001
NL–UK: 0.572
HR–UK: 0.035
Slightly likely 87 (13) 11 (8) 41 (22) 17 (17)
Moderately likely 189 (29) 54 (40) 44 (24) 27 (27)
Very likely 341 (52) 67 (49) 83 (44) 48 (48)
Data are given as n (%)
ADRs adverse drug reactions, DHPCs direct healthcare professional communications, HR Croatia, NCA national competent authority, NL
Netherlands, PIL patient information leaflet
aAll European responders
bThe number of responders who do not want to use an app to report ADRs was 22, the number of responders that selected ‘none’ was 27 and 36
selected ‘Other’
cPercentages are calculated excluding the responders who selected ‘None’ and those who selected ‘I do not want to use an app to report side
effects/receive safety information’
d24 responders selected ‘None’, 20 responders selected ‘I do not want to use an app to receive safety information’ and 15 selected ‘Other’
e39 responders indicated that they do not want to receive safety information through an app and 29 selected ‘Other’
fPercentages are calculated excluding the responders who selected ‘Other’
g27 responders indicated ‘Not applicable’ and 24 responders selected ‘Other’
hPercentages are calculated excluding those who selected ‘Not applicable’ and ‘Other’
i1 responder did not complete this question, 26 were not interested in any other function and 64 selected ‘Other’
jPercentages are calculated excluding those who selected ‘None/No other functions/I do not want to receive safety information through an app’
k4 responders did not answer this question and 65 responders selected ‘Other’
l2 responders did not complete this question
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this HCP characteristic was statistically significant for The
UK only (OR 9.50; 95% CI 3.11–29.05) (Electronic Sup-
plementary Material 5). The generalised ordered logit
model showed a similar influence of the use of health apps
on the different levels of the outcome measure (Electronic
Supplementary Material 6).
3.4.2 Patient Characteristics
Age and use of health apps were the patient characteristics
significantly associated with interest in the app. Older
patients were less often very interested in the app than
younger patients (OR 0.98; 95% CI 0.97–0.997). Patients
who at least sometimes use a health app were more often
very interested than those who never use a health app (OR
1.64; 95% CI 1.19–2.27) (Fig. 2b). The country-specific
analyses showed a statistically significant association of the
use of health apps for The Netherlands only (OR 2.20; 95%
CI 1.13–4.27) (Electronic Supplementary Material 7).
Additional statistically significant associations were shown
for The UK, where patients with a tertiary education level
were less often very interested than patients with a low or
Age
Female vs. Male
At least sometimes use 
of health apps vs. Never
ADR reported to agency 
vs. Not 
Odd raos (95% CIs)Determinants
N = 390
1.00 (0.98-1.02)
1.20 (0.76-1.89)
3.52 (1.96-6.30)
1.52 (0.94-2.47)
0,01 0,1 1 10 100
Odds raos with 95% conﬁdence intervals (log scale)
 r rt  t  c  vs. Not
At least so eti es use of health app vs. Never
Age
Female vs. Male
Tertiary education vs. 
Low/secondary 
0 medicines vs. 1-4 
≥5 medicines vs. 1-4
At least sometimes use 
of health apps vs. Never
ADR experienced vs. Not
Aware of reporting to 
agency vs. Not
Odd raos (95% CIs)Determinants
N = 636
0.98 (0.97-0.997)
1.14 (0.81-1.62)
0.75 (0.53-1.05)
0.69 (0.43-1.09)
1.02 (0.70-1.48)
1.64 (1.19-2.27)
1.47 (0.97-2.21)
1.17 (0.84-1.62)
0,01 0,1 1 10 100
Odds raos with 95% conﬁdence intervals (log scale)
At least sometimes use of health apps vs. Never
Aware of reporting to agency vs. Not
Tertiary education vs. Low/secondary 
a Healthcare professionals
b Paents
Fig. 2 Odds ratios with 95% confidence intervals of associations
between a healthcare professional characteristics and being very
interested in an app for two-way risk communication and b patient
characteristics and being very interested in this app. ADR adverse
drug reaction, CI confidence interval
Interest in an App for Two-Way Risk Communication
secondary education level (OR 0.20; 95% CI 0.05–0.81),
and patients who take no medicines were less often very
interested than patients who take one to four medicines
(OR 0.17; 95% CI 0.04–0.75). The generalised ordered
logit model showed a similar effect of use of health apps on
the different levels of the outcome measure but showed
different patterns for other characteristics (Electronic
Supplementary Material 6).
4 Discussion
This study showed that HCPs and patients were generally
interested in an app for two-way risk communication and
that, in particular, HCPs and patients who already use a
health app are more interested in such an app. A main
benefit for HCPs and patients of the reporting functionality
in the app was that it can make the ADR reporting process
faster and easier. Previous studies have shown that lack of
time and difficulty in accessing reporting forms are the
main barriers for HCPs to spontaneously report ADRs to
national pharmacovigilance centres [12–14]. In contrast,
literature suggests that patients may be willing to spend
more time on reporting an ADR than HCPs [2] and one of
the reasons for patients to spontaneously report an ADR is
when they have the impression that HCPs have too limited
time to accurately report ADRs [15]. However, in this
study patients also preferred a reporting tool that is easy
and fast to complete.
With respect to the information functionality of the app,
HCPs would like the app to keep them up-to-date with the
latest news and that it will increase their knowledge about
drug safety. In addition, most HCPs liked to receive news
about (newly identified) drug–drug interactions. Previ-
ously, it has been shown that HCPs’ awareness of drug
safety issues, for instance those communicated through
direct healthcare professional communications (DHPCs),
are suboptimal [16] as is their knowledge about drug–drug
interactions [17]. Our study suggests that HCPs are aware
of their lack of knowledge and that an app could be a tool
to improve this.
Patients particularly liked an overview of ADRs previ-
ously reported by others, and patient information leaflets as
information in an app. They indicated that a main benefit of
the app would be to allow them to check whether a
symptom was previously reported as an ADR. These
findings are in line with previous studies showing that
patients are sometimes uncertain about an association
between a symptom and a drug [18–21], and may be
uncertain about the exact drug causing the symptoms [22].
Providing such information in an app could reduce
patients’ uncertainty in confirming that their symptoms are
caused by the drug(s) they are taking. Also, a previous
study showed that one-third of patients did not discuss their
medication symptoms with an HCP [23]. Almost half of the
patients in our study indicated that the app could increase
their confidence when talking to their HCP. This increased
certainty about an ADR may improve the patient–HCP
conversation about ADRs. In addition, it may increase
patient reporting of ADRs to the national pharmacovigi-
lance centres, but future studies will be needed to investi-
gate such effects.
HCPs’ and patients’ preferences and perceptions
towards the characteristics of the app in general were rel-
atively similar. This suggests that the functionality of the
app can be similar for HCPs and patients. However, the
type of drugs for which responders would like to receive
safety information differed between HCPs and patients, as
HCPs liked the option to receive information for all drugs
more. It should be possible to incorporate such user-
specific preferences into the app. In addition, differences in
other aspects of the app, such as appropriate terminology
for these target groups, need to be considered [2].
Our finding that HCPs and patients who already use a
health app are particularly interested in an app for two-way
risk communication suggests that, in particular, those HCPs
and patients may well be the most receptive group that
should be informed about the existence of such an app.
This could, for instance, be done via advertisements or a
link to the app in other health apps. The high number of
responders that liked other functionalities in an app for
two-way risk communication also suggests that links to
various other health apps may increase its usefulness. Ways
to stimulate the interest of non-app users and encouraging
their participation could benefit from further investigation.
4.1 Strengths and Limitations
A strength of this study is the assessment of interest in the
app among both HCPs and patients. In addition, this is a
first study assessing the role of user characteristics on the
use of an app for two-way risk communication. Although
we collected data from a large sample of HCPs and
patients, a limitation is that the number of responders per
country was still relatively low. Another limitation of this
study was its methodology of a cross-sectional survey. We
cannot be sure how representative it was of the studied
countries. We present data for a subgroup of three countries
in which the app was already available, but differences
between countries should be interpreted cautiously since
the characteristics of the responders differ across these
countries. Moreover, the number of responders from
countries other than the three countries in which the app
was available was low. Therefore, it cannot be assumed
that the included population is a representative sample of
the European populations. Also, we do not have any
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numbers relating to response rates since HCPs and patients
were reached via various channels including advertise-
ments and announcements. Furthermore, survey-answering
tendencies may differ across countries, as has been shown
previously [24]. Another limitation relates to the assess-
ment of interest in the app. First, we could not use a val-
idated measure to assess interest in the app since, to our
knowledge, such a measure is not available. Second,
interest is a first step for actually downloading and using
the app but its actual use may be influenced by other factors
[3]. Therefore, future studies are needed to evaluate the
actual use of the app in different countries.
5 Conclusions
HCPs and patients in Europe are generally interested in an
app for two-way risk communication, which supports its
further development. Such an app should support easy and
fast reporting of ADRs and provide information about
drug–drug interactions and previously reported ADRs to its
users. HCPs and patients who already use other health apps
are particularly interested in the app. Therefore, dissemi-
nation strategies could focus on reaching these HCPs and
patients.
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